In addition, the label is updated to include data from SELECT showing a risk reduction in cardiovascular death by 15% and a risk reduction of death from any cause by 19%, both compared to placebo (Cardiovascular death superiority not confirmed (hazard ratio: 0.85 (0.71;1.01) and death by any cause not statistically significant based on the prespecified testing hierarchy (hazard ratio: 0.81 (0.71
The pharmacological effects of Wegovy create an environment conducive to weight loss, but dietary modification remains essential
Tesamorelin is the exception that proves the rule: a growth-hormone-releasing hormone analog with an actual FDA label, but narrowly for HIV-associated lipodystrophy (excess visceral fat), not general weight loss
Molecular mechanisms of insulin resistance in type 2 diabetes mellitus
Clinical evidence from the STEP trials demonstrated that participants on semaglutide lost significantly more weight than those on placebo, with benefits sustained over 2+ years of continuous therapy
Dazu verbessern sie die Leberwerte, senken die Blutfette, verlangsamen die Plaquebildung in den Arterien mglicherweise durch anti-inflammatorische Effekte, vergleichbar mit Statinen und strken die Nierenfunktion
